MarketPulse

public offering

49 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Bimergen Energy to List on NYSE American After $13.6M Offering

Bimergen Energy prices $13.6M IPO at $4 per share, listing on NYSE American February 20. Proceeds fund battery energy storage projects.
BESSwarrantspublic offering
BenzingaBenzinga··Globe Newswire

Candel Therapeutics Plans $100M Stock Offering to Fund Cancer Treatment Pipeline

Candel Therapeutics plans $100M stock offering to fund cancer treatment pipeline development, particularly for prostate and lung cancer therapies.
CADLclinical trialpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Pharmaceuticals Raises $55M Through Public Offering to Fund GI Pipeline

Eupraxia Pharmaceuticals raises $55M via public offering to advance EP-104GI for eosinophilic esophagitis through Phase 2/3 development and expand GI pipeline.
EPRXclinical trialspublic offering
BenzingaBenzinga··Globe Newswire

Coherus Oncology Raises $50.1M in Stock Offering to Fund Oncology Pipeline

Coherus Oncology raised $50.1M through stock offering to fund commercial launch of LOQTORZI and advance its oncology pipeline development.
CHRSclinical developmentpublic offering
BenzingaBenzinga··Globe Newswire

Liminatus Pharma Prices $4M Share Offering to Fund Immuno-Oncology Pipeline

Liminatus Pharma prices $4M share offering to fund immuno-oncology pipeline development, specifically advancing CD47-blockade therapeutic programs.
LIMNLIMNWwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Strengthens Balance Sheet With $172.5M Offering; Eyes Mid-2027 Cash Runway

Inventiva raises $172.5M, strengthening balance sheet to €230.9M in liquidity. Clinical-stage biotech projects cash runway through mid-2027 to advance MASH treatment program.
IVApublic offeringclinical-stage biopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BioRestorative Closes $5M Equity Offering to Fund Stem Cell Pipeline

BioRestorative raised $5M through equity offering to advance stem cell therapies, including BRTX-100 for spine disease and metabolic disorder research.
BRTXclinical trialsregenerative medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Okyo Pharma Limited

OKYO Pharma Prices $20M Share Offering to Fund Clinical Development

OKYO Pharma prices $20M share offering to fund clinical development of urcosimod for neuropathic corneal pain treatment, advancing Phase 2b/3 trial.
OKYOPIPRclinical developmentpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Coherus Oncology Raises $50.1M Through Common Stock Offering

Coherus Oncology raises $50.1M via stock offering to fund commercial expansion of LOQTORZI and advance oncology pipeline development programs.
CHRSclinical developmentpublic offering